Additionally, Rakovina has partnered with Fairfax Partners Inc. for a comprehensive investor relations program aimed at expanding its market presence and investor base. Fairfax will receive a monthly fee and a marketing budget to support Rakovina's strategic goals through various marketing and communication initiatives. The company aims to progress its drug candidates into clinical trials and secure regulatory approvals, with a focus on enhancing shareholder value through innovative cancer care solutions.
Key takeaways:
```html
- Rakovina Therapeutics Inc. has closed an oversubscribed $3 million private placement, consisting of 50,000,000 units at $0.06 per unit, each including one common share and one purchase warrant.
- The proceeds from the private placement will be used to accelerate the discovery and development of Rakovina's proprietary drug candidates, leveraging AI technologies.
- Rakovina has engaged Fairfax Partners Inc. for a comprehensive six-month investor relations program to enhance market presence and expand its investor base.
- The private placement is subject to final acceptance by the TSX Venture Exchange, with all securities subject to a hold period of four months plus one day from issuance.